pitavastatin and 1-anilino-8-naphthalenesulfonate

pitavastatin has been researched along with 1-anilino-8-naphthalenesulfonate* in 2 studies

Other Studies

2 other study(ies) available for pitavastatin and 1-anilino-8-naphthalenesulfonate

Article	Year
The Phenomenon of Albumin-Mediated Hepatic Uptake of Organic Anion Transport Polypeptide Substrates: Prediction of the In Vivo Uptake Clearance from the In Vitro Uptake by Isolated Hepatocytes Using a Facilitated-Dissociation Model. Drug metabolism and disposition: the biological fate of chemicals, 2018, Volume: 46, Issue:3 The effects of bovine serum albumin and human serum albumin on the unbound hepatic uptake clearance ( Topics: Albumins; Anilino Naphthalenesulfonates; Animals; Biological Transport; Cells, Cultured; Hepatocytes; Humans; Kinetics; Liver; Male; Metabolic Clearance Rate; Organic Anion Transporters; Quinolines; Rats; Rats, Sprague-Dawley	2018
Extrapolation of the Hepatic Clearance of Drugs in the Absence of Albumin In Vitro to That in the Presence of Albumin In Vivo: Comparative Assessement of 2 Extrapolation Models Based on the Albumin-Mediated Hepatic Uptake Theory and Limitations and Mechan Journal of pharmaceutical sciences, 2018, Volume: 107, Issue:7 The extrapolation of hepatic clearance (CL) from data determined in an in vitro assay in the absence of albumin (ALB) to that in the presence of ALB in liver in vivo was often inaccurate using traditional in vitro-to-in vivo extrapolation (IVIVE) methods for drugs binding to the ALB. It is recognized that considering an ALB-facilitated hepatic uptake phenomenon in the IVIVE can improve the extrapolation. Therefore, the present study provides a comparison of 2 existing models that account for the ALB-facilitated hepatic uptake phenomenon in the IVIVE of CL. These models assume an interaction of the ALB-bound drug complex with the hepatocyte membrane that enhanced the dissociation of the drug from ALB to result in increased unbound intracellular drug levels available for metabolism or transporter-mediated elimination. One model refers to the old facilitated-dissociation model (FDM), which is based on a binding isotherm and necessitates knowing the specific input parameters of the interaction (i.e., relative capacity of the interaction, dissociation constant, number of binding sites, and ALB concentration). The other model is based on the same theory but is recent and more speculative although it presumes that each interaction between the ALB-drug complex and the hepatocyte surface would at all times enhance and deliver the dissociated bound drug moiety into the hepatocytes and therefore, has the advantage to use less binding information. Consequently, this second model simply consists of adjusting the unbound fraction determined in plasma in vitro of each drug (fu Topics: Albumins; Anilino Naphthalenesulfonates; Animals; Biological Transport; Fluorescent Dyes; Hepatocytes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinetics; Liver; Metabolic Clearance Rate; Models, Biological; Protein Binding; Quinolines; Rats	2018

Article

Year

The Phenomenon of Albumin-Mediated Hepatic Uptake of Organic Anion Transport Polypeptide Substrates: Prediction of the In Vivo Uptake Clearance from the In Vitro Uptake by Isolated Hepatocytes Using a Facilitated-Dissociation Model.

Drug metabolism and disposition: the biological fate of chemicals, 2018, Volume: 46, Issue:3

The effects of bovine serum albumin and human serum albumin on the unbound hepatic uptake clearance (

Topics: Albumins; Anilino Naphthalenesulfonates; Animals; Biological Transport; Cells, Cultured; Hepatocytes; Humans; Kinetics; Liver; Male; Metabolic Clearance Rate; Organic Anion Transporters; Quinolines; Rats; Rats, Sprague-Dawley

2018

Extrapolation of the Hepatic Clearance of Drugs in the Absence of Albumin In Vitro to That in the Presence of Albumin In Vivo: Comparative Assessement of 2 Extrapolation Models Based on the Albumin-Mediated Hepatic Uptake Theory and Limitations and Mechan

Journal of pharmaceutical sciences, 2018, Volume: 107, Issue:7

The extrapolation of hepatic clearance (CL) from data determined in an in vitro assay in the absence of albumin (ALB) to that in the presence of ALB in liver in vivo was often inaccurate using traditional in vitro-to-in vivo extrapolation (IVIVE) methods for drugs binding to the ALB. It is recognized that considering an ALB-facilitated hepatic uptake phenomenon in the IVIVE can improve the extrapolation. Therefore, the present study provides a comparison of 2 existing models that account for the ALB-facilitated hepatic uptake phenomenon in the IVIVE of CL. These models assume an interaction of the ALB-bound drug complex with the hepatocyte membrane that enhanced the dissociation of the drug from ALB to result in increased unbound intracellular drug levels available for metabolism or transporter-mediated elimination. One model refers to the old facilitated-dissociation model (FDM), which is based on a binding isotherm and necessitates knowing the specific input parameters of the interaction (i.e., relative capacity of the interaction, dissociation constant, number of binding sites, and ALB concentration). The other model is based on the same theory but is recent and more speculative although it presumes that each interaction between the ALB-drug complex and the hepatocyte surface would at all times enhance and deliver the dissociated bound drug moiety into the hepatocytes and therefore, has the advantage to use less binding information. Consequently, this second model simply consists of adjusting the unbound fraction determined in plasma in vitro of each drug (fu

Topics: Albumins; Anilino Naphthalenesulfonates; Animals; Biological Transport; Fluorescent Dyes; Hepatocytes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinetics; Liver; Metabolic Clearance Rate; Models, Biological; Protein Binding; Quinolines; Rats

2018